We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+19.88%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.1B
AUM Growth
+$208M
Cap. Flow
+$144M
Cap. Flow %
13.12%
Top 10 Hldgs %
54.38%
Holding
136
New
36
Increased
27
Reduced
26
Closed
32

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$35.5M
2
NVO
Novo Nordisk
NVO
+$19.7M
3
URGN icon
UroGen Pharma
URGN
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$12.4M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$10.9M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$19.7M
2
CELG
Celgene Corp
CELG
+$18.8M
3
ITRN icon
Ituran Location and Control
ITRN
+$14.6M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$11.6M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 55.27%
2 Technology 6.57%
3 Consumer Discretionary 1.18%
4 Industrials 1.08%
5 Communication Services 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTEM
126
DELISTED
Molecular Templates, Inc.
MTEM
– –
-26,667
Closed -$1.62M
EPZM
127
DELISTED
Epizyme, Inc
EPZM
– –
-749,502
Closed -$4.62M
SRRA
128
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-6,463
Closed -$341K
TBIO
129
DELISTED
Translate Bio, Inc. Common Stock
TBIO
– –
-309,400
Closed -$2.32M
GWPH
130
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-77,000
Closed -$7.5M
UROV
131
DELISTED
Urovant Sciences Ltd.
UROV
– –
-214,030
Closed -$1.41M
PTLA
132
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-147,000
Closed -$2.87M
MLNT
133
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
– –
-323,373
Closed -$1.28M
DOVA
134
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
– –
-185,000
Closed -$1.4M
ARRY
135
DELISTED
Array Biopharma Inc
ARRY
– –
-125,000
Closed -$1.78M
2 3 4 5
6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2019 Portfolio in Review

As of Q1 2019, Sphera Funds Management held 136 positions worth $1.1B, up 23% from $887M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sphera Funds Management deployed $144M of net new capital in Q1 2019, opening 36 new positions and adding to 27 existing holdings. Its largest new stake was Johnson & Johnson: 265,000 shares worth $37M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 60% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Viatris, an estimated $19.7M trimmed.

  • Sphera Funds Management's largest Q1 2019 buy was Johnson & Johnson: 265,000 shares worth $37M.
  • Sphera Funds Management added most to Bristol-Myers Squibb in Q1 2019, an estimated $12.4M increase.
  • Sphera Funds Management's biggest Q1 2019 reduction was Viatris, cutting an estimated $19.7M.
  • Sphera Funds Management fully exited Ituran Location and Control in Q1 2019, selling an estimated $14.6M.
  • Sphera Funds Management's ten largest holdings make up 54% of its $1.1B portfolio in Q1 2019.
  • Sphera Funds Management opened 36 new positions and closed 32 in Q1 2019.
  • Sphera Funds Management's portfolio value rose 23% quarter-over-quarter to $1.1B.

Based on Sphera Funds Management's 13F filing for Q1 2019, filed 15 May 2019.